![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
系统性向疗法在复发/耐药的晚期皮肤T细胞淋巴瘤患者:一个现实世界的单中心病例系列
Signe Hedebo1, Martin B Pedersen2, Lise M Lindahl3
1Department of Dermatology and Venereology Aarhus University Hospital, Aarhus, Denmark; Aarhus University, Aarhus, Denmark. siheha@rm.dk.
Acta dermato-venereologica
|March 13, 2025
概括
系统性向疗法,如mogamulizumab,brentuximab vedotin和alemtuzumab在晚期皮肤T细胞淋巴瘤中表现出有效性. 阿莱姆图祖马布,特别是在低剂量方案中,在复发或耐药性疾病患者中表现出有希望的结果.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 血液学 血液学 血液学
背景情况:
- 皮肤T细胞淋巴瘤 (CTCL) 是一组多样化的非霍奇金淋巴瘤.
- 早期的CTCL通常通过局部治疗来治疗,而晚期需要全身疗法.
- 系统性抗体向疗法对于晚期,复发或耐火性CTCL至关重要.
研究的目的:
- 评估使用全身向疗法治疗晚期CTCL患者的现实结果.
- 为了比较mogamulizumab,brentuximab vedotin和alemtuzumab在临床环境中的有效性.
- 为了突出管理先进CTCL的复杂性,使用当前的全身治疗.
主要方法:
- 阿尔胡斯大学医院27名患者的回顾性队列病例系列 (2013-2023).
- 患者患有复发性/耐药性晚期CTCL,主要是塞萨里综合征或真菌菌菌病.
- 对接受mogamulizumab,brentuximab vedotin或alemtuzumab的患者结果的分析.
主要成果:
- 总体响应率为mogamulizumab的78%,为brentuximab vedotin的65%,为alemtuzumab的61%.
- 病情进展的中位时间为mogamulizumab的2.5个月,brentuximab vedotin的4个月和alemtuzumab的11个月.
- 六名患者接受了一次以上的全身向治疗,表明复杂的治疗途径.
结论:
- 系统性向疗法在管理晚期CTCL方面是有效的.
- 阿莱姆图祖马布,特别是在低剂量方案中,对晚期CTCL显示出特别有前途的结果.
- 该研究提供了关于高级CTCL管理临床实践复杂性的见解.
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:27Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K